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ABSTRACT:
A transgenic mouse model of mammary carcinoma (MTAG) was chosen to study host -tumor interactions over an extended period where the immune system interacts continuously with a developing and progressive malignancy. MTAG mice develop multiple mammary tumors with disease progression to pulmonary metastases and better represent natural disease progression than many of the current tumor implant models. Splenocyte number was found to increase concurrently with increasing tumor burden, mainly due to an expansion in the number of 
INTRODUCTION:
A review of the current literature on breast cancer initiation and progression highlights the complex nature of the interactions between a tumor and the host immune system. Although the study of tumorigenic cell lines has given some insights on the immunobiology of breast cancer, these systems cannot reflect the intricacy of long-term in vivo host -tumor interactions that occur during cancer development and progression. Genetically engineered mouse models of mammary cancer have therefore become important tools in the study of breast cancer biology and immunobiology 1, 2 . The MTAG mouse was created using the MMTV-LTR promotor to specifically target expression of the polyoma virus middle T antigen oncogene to mammary tissue 3 . Mammary tumors develop in 100% of transgenic mice with >95% progression to pulmonary metastases, over an average 6-month lifespan. Tumor histopathology of these mice has been shown to mimic that of human breast carcinoma at both morphological (disease stage) and molecular levels 4 The MTAG model allows the study of host -tumor interactions over an extended period where the immune system interacts continuously with a developing and progressive malignancy.
This environment of chronic interactions better reflects a human disease setting than many of the current tumor implant models where the host is 'assaulted' by an acute tumor cell challenge. As a validation of the relevancy of this MTAG mouse as a model for pre-clinical studies, we investigated the consequences of tumor development and progression on the immune system, including the development of suppressive immune cell types and mediators of inflammation that have been associated with a poor prognosis in breast cancer patients. Examples of suppressive immune cell types include tumor-associated macrophages (TAMS) 5, 6 , myeloid suppressor cells 7, 8 , natural killer (NK)T cells 9, 10 and regulatory T (Treg) cells [11] [12] [13] .
The growth of most tumors can be associated with an inflammatory reaction 14 , which can have both pro-and anti-tumor affects. Indeed, an anti-tumor immune response requires certain inflammatory messages to develop effectively 15 ; however, there is mounting evidence that tumor cells and/or tumor-associated leukocytes can also produce inflammatory cytokines and chemokines that promote malignant progression. In human breast cancer increased sera levels of the inflammatory chemokine, monocyte-chemoattractant protein-1 (MCP-1), has been linked with poor prognosis 16, 17 . MCP-1 is a CC chemokine described as a potent macrophage recruiting molecule 18, 19 and has been associated with increased angiogenesis and tumor growth rate 16, 20 . TNF- is another inflammatory mediator that has been detected in tumor and/or stromal cells of a number of human cancers including breast, ovarian and colorectal 21, 22 . There is also evidence that TNF- has pro-tumorigenic actions [23] [24] [25] [26] [27] and an association with poor prognosis 28 . Therefore this study included an analysis of serum levels of a number of inflammatory mediators including MCP-1 and TNF-.
These studies outline some of the immunological consequences of disease progression in a mouse model of spontaneously arising and progressive mammary carcinoma. Our data support the hypothesis that tumor development and progression systemically influence the content and function of various immune cell populations, the development of immunosuppressive cell types, and the production of systemic pro-inflammatory cytokines. These changes reveal the complexity of host-tumor interactions, and indicate that a multitude of immune consequences emerge, consistent with a tumor-induced "immunological syndrome". However, many of these changes occurred during late-stage disease when tumor burden was extensive, suggesting that therapies may be more efficacious if earlier stages of disease are targeted, when immune performance is less likely to be compromised.
MATERIALS and METHODS: Mice
Transgenic MTAG mice on a C57BL/6 background contain the Polyoma Virus Middle T Antigen (PyMT) controlled through the MMTV Promoter (LTR) 3 and were a kind gift of Dr. S. staining was conducted using the FoxP3 staining kit (eBiosciences, San Diego, CA) and following manufacturer protocol. All samples were run with appropriate isotype controls.
Cytokine analysis
Splenocytes were cultured in an anti-CD3 (1 μg/ml) pre-coated 24 well plate, which contained 10 g/ml anti-CD28 and 2 x 10 6 cells in 1 ml of cRPMI, at 37 
Statistical analysis
Tumor volumes were calculated using W 2 x L / 2, where W=width and L=length of tumor mass measured in millimeters. Total tumor volume equals the sum of each individual tumor volume, which in the case of MTAG transgene positive mice could be up to 10 tumors. A two-tailed student's t test was performed on sample comparisons to determine statistically significant differences. A probability level (p) of less than 0.05 was considered statistically significant.
RESULTS & DISCUSSION:
Tumor growth in the MTAG transgenic mouse Table 2 ]. Therefore, as total tumor burden and splenocyte number increased, there was a concomitant amplification in both the percentage and absolute number of this population, as determined by CD11b-staining [ Table 2 & Fig.3 ]. This resulted in a corresponding decrease in the percentage of T cells, although the absolute number of T lymphocytes remained constant. This is in contrast to several tumor implant models and reports on human disease progression 34, 35 , where a decrease in the absolute number of peripheral T cells was observed.
No bias in the reduction of a particular T cell subpopulation was observed because the percentages of both CD4 + and CD8 + T cell subsets were similarly decreased, and the CD4/CD8
cell ratio was maintained [ Table 2 ]. The changes in splenocyte populations were more strikingly represented when CD3/CD11b ratios were determined. However, the increase in CD11b + cell number became evident only in mice with a relatively high tumor burden (i.e., >2 cm 3 ) [ Fig. 3 ], which contrasts with some tumor implant models where this increase is seen in mice with much lower tumor loads 32, 33 . The majority of these CD11b + cells were found to be Gr1 + with their percentage and absolute number increasing progressively with increasing total tumor burden. Mouse B) compared with Tg -control mice. This indicated that the reduced proliferative capacity of these cells had either a qualitative aspect or was due to the presence of a suppressive cell type.
Since reduced proliferation was seen in the splenocyte preparations with similar T cell numbers, and because purified T cells from such mice displayed comparable proliferative capacity when compared to control preparations (submitted manuscript), these data lends further evidence for the presence of a suppressive cell type/s, within the splenocyte preparations, that was responsible for the reduced proliferative capacity of splenocytes from the spleens of tumor-bearing mice.
There was no obvious impairment of immune function in Tg + mice due to transgene expression since cells from aged Tg -and young Tg + or Tg -mice exhibited similar proliferative capacity [ Fig.5C ]. Because the suppressed response was observed with bulk splenocytes, these mixed populations would also be present in the spleen in vivo; we therefore postulate that a similar in vivo suppressive effect on T cell function can occur. Immune suppression is also supported by the observation that lymphoadenopathy occurs during early disease but then lymph node size and LNC number is reduced in mice with late stage or extensive tumor burden
[ Fig.2A ]. These suppressed immune responses may explain, at least in part, the lack of consistently successful cancer immunotherapies, which by their very nature require the ability of the host to mount a competent immune response.
Changes in suppressive cell types as tumors progressed
There are a number of suppressive cell types that have been reported to have immune inhibitory activity in tumor-bearing animal models and cancer patients. These include Treg cells (CD4 + CD25 + FoxP3 + ) 11, 12 , NKT cells 9, 10 and CD11b + Gr1 + myeloid suppressor cells (MSCs) 7, 8 . An analysis of these populations within the MTAG model showed that the percentage of NKT cells in both the spleen and TDLNs was not significantly different between tumor-bearing and control mice [ Table 2 & Fig.4 ], although a change in their function could not be ruled out. 
Tumor-bearing animals demonstrated increased serum levels pro-inflammatory cytokines
There is mounting evidence for a link between inflammation and an increased incidence 41 . MCP-1 can also inhibit the generation of tumor-reactive T cells 46 and polarize immunity in a type II direction 47 . Therefore, increased levels of MCP-1 in the blood may skew the immune system towards a type II inflammatory response that may undermine effective type I and anti-tumor defense mechanisms 48 . Indeed, MCP-1 expression has been related to tumor aggressiveness in a number of tumor types including carcinoma of the breast, bladder and ovaries 49 . MCP-1 and other inflammatory mediators, or the pathological consequences of their presence, may therefore be targets for anti-tumor therapy and have already been used as a measure of therapeutic efficacy.
CONCLUSIONS:
In 
